# New carcinoma clinical trials, last 30 days: 126 (2026)

Updated November 19, 2026.

126 new trials for carcinoma were first posted on ClinicalTrials.gov in the 30 days from October 20, 2026 to November 18, 2026, as read on November 19, 2026.

## The full list

New carcinoma clinical trials, last 30 days: 126 rows for $6.30, first posted from October 20, 2026 to November 18, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 15 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/new/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 126
- Recruiting or not yet: 114
- Read on: November 19, 2026

## Trials

The 25 newest of 126, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 18, 2026 | NCT07947121 | A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer... | GlaxoSmithKline | Phase 3 | Not yet recruiting | Lung Neoplasm | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947121) |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 18, 2026 | NCT07946445 | Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde... | Institute of Liver and Biliary Sciences, India | Observational | Not yet recruiting | Choledocholithiasis, Biliary Stricture, Chronic Pancreatitis, Periampullary Carcinoma, Cholangiocar.... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946445) |
| November 18, 2026 | NCT07944677 | Metabolism And Diet for Improving Kidney Cancer Health (MACH3) | University of Miami | Not applicable | Not yet recruiting | Renal Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944677) |
| November 18, 2026 | NCT07944313 | Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung... | Quanzhou First Hospital | Phase 2 | Not yet recruiting | Non-Small Cell Carcinoma of Lung | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944313) |
| November 17, 2026 | NCT07943325 | Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Goethe University | Phase 3 | Not yet recruiting | Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943325) |
| November 17, 2026 | NCT07943143 | Histotripsy for Renal Cell Carcinoma | The University of Hong Kong | Not applicable | Recruiting | Localised or Metastatic Renal Cell Carcinoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943143) |
| November 17, 2026 | NCT07942025 | 90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma | Beijing Tsinghua Chang Gung Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07942025) |
| November 17, 2026 | NCT07941830 | AI-Based Anatomy Recognition in Minimally Invasive Kidney Surgery | Chinese PLA General Hospital | Observational | Not yet recruiting | Kidney (Renal Cell) Cancer, Ureteropelvic Junction Obstruction, Upper Urinary Tract Carcinoma | 1,700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941830) |
| November 17, 2026 | NCT07941609 | A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC | AstraZeneca | Phase 2 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941609) |
| November 17, 2026 | NCT07940881 | A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SI-B037 in Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, First in Human, Metastatic Solid... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940881) |
| November 16, 2026 | NCT07940478 | A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for... | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Hepatecellular Carcinoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940478) |
| November 16, 2026 | NCT07940348 | Supine Versus Prone Whole-Breast Radiotherapy in Thai Women After Breast-Conserving Surgery | Mahidol University | Not applicable | Not yet recruiting | Breast Cancer, Ductal Carcinoma In Situ | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940348) |
| November 16, 2026 | NCT07940257 | Study of Furmonertinib as Follow-Up Treatment After Surgery for Early-Stage EGFR-Positive Lung Cancer: Real-World Observation | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Observational | Active not recruiting | NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Early Stage Lung Non-Small Cell Carcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940257) |
| November 16, 2026 | NCT07940036 | Skin Cancer Detection in Primary Care With and Without DermaSensor | DermaSensor, Inc. | Not applicable | Not yet recruiting | Skin Cancer, Basal Cell Cancer, Squamous Cell Carcinoma, Melanoma (Skin Cancer), Melanoma In Situ, Melanoma Detection... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940036) |
| November 16, 2026 | NCT07939997 | ctDNA Observational Biomarker Validation Study for Evaluation of Esophageal Squamous Cell Carcinoma | University of Colorado, Denver | Observational | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939997) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 16, 2026 | NCT07939204 | A Single-Arm Phase II Clinical Study of Sacituzumab Tirumotecan Combined With a PD-1 Inhibitor as Second-Line Therapy for Advanced... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939204) |
| November 16, 2026 | NCT07938463 | Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | ALK Positive Non-small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938463) |
| November 16, 2026 | NCT07938385 | Characterisation of Immunological and Molecular Changes Evolving in Patients Undergoing Radiotherapy (CHIMERA) | Royal Marsden NHS Foundation Trust | Observational | Recruiting | Impact of the Immune Cell Repertoire on the Therapeutic Index of Radiotherapy, The Need for Serum Markers of... | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938385) |
| November 16, 2026 | NCT07937553 | Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma. | Kidney Cancer Research Bureau | Phase 2 | Recruiting | Metastatic Chromophobe Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07937553) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| November 13, 2026 | NCT07936422 | A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients | Centre Leon Berard | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936422) |
| November 13, 2026 | NCT07934966 | Pulmonary Ligament Division vs Preservation in Upper Lobectomy | Ain Shams University | Not applicable | Completed | Lobectomy, Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Volume | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934966) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 21 |
| Phase 1/2 | 9 |
| Phase 2 | 33 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |
| Phase 4 | 1 |
| Not applicable | 22 |
| Observational | 26 |

## Sponsors posting most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 6 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| Peking University Cancer Hospital & Institute | 3 |
| Sun Yat-sen University | 3 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| Kidney Cancer Research Bureau | 2 |
| Guizhou Medical University | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 2 |
| Samsung Medical Center | 2 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 2 |
| Second Xiangya Hospital of Central South University | 2 |
| Immuneering Corporation | 1 |
| Institute of Liver and Biliary Sciences, India | 1 |
| University of Miami | 1 |
| Quanzhou First Hospital | 1 |
| Goethe University | 1 |
| The University of Hong Kong | 1 |
| Beijing Tsinghua Chang Gung Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| SystImmune Inc. | 1 |
| Fujian Cancer Hospital | 1 |
| Mahidol University | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Behavior analysis services in the United States](https://specstream.ai/data/businesses/behavior-analysis-services/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Tableware suppliers in the United States](https://specstream.ai/data/businesses/tableware-suppliers/united-states)
- [Psychiatric hospitals in the United States](https://specstream.ai/data/businesses/psychiatric-hospitals/united-states)
- [Natural gas utilities in the United States](https://specstream.ai/data/businesses/natural-gas-utilities/united-states)
- [Insurance agencies in the United States](https://specstream.ai/data/businesses/insurance-agencies/united-states)
